These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1311687)

  • 81. The binding of SCH 39166 and SCH 23390 to 5-HT1C receptors in porcine choroid plexus.
    Taylor LA; Tedford CE; McQuade RD
    Life Sci; 1991; 49(20):1505-11. PubMed ID: 1943454
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of ethanol administration and withdrawal on serotonin receptor subtypes and receptor-mediated phosphoinositide hydrolysis in rat brain.
    Pandey SC; Piano MR; Schwertz DW; Davis JM; Pandey GN
    Alcohol Clin Exp Res; 1992 Dec; 16(6):1110-6. PubMed ID: 1335222
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine.
    Bourson A; Wanner D; Wyler R; Petit N; Zwingelstein C; Rudler A; Sleight AJ
    Pharmacol Biochem Behav; 1996 Jan; 53(1):107-14. PubMed ID: 8848438
    [TBL] [Abstract][Full Text] [Related]  

  • 84. 5-HT2 receptor antagonists and migraine therapy.
    Mylecharane EJ
    J Neurol; 1991; 238 Suppl 1():S45-52. PubMed ID: 2045831
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Serotonin receptor activation of phosphoinositide turnover in uterine, fundal, vascular, and tracheal smooth muscle.
    Cohen ML; Wittenauer LA
    J Cardiovasc Pharmacol; 1987 Aug; 10(2):176-81. PubMed ID: 2441168
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
    Sanders-Bush E; Breeding M
    Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [125I]SCH 23982, a 'selective' D-1 receptor antagonist, labels with high affinity 5-HT1C sites in pig choroid plexus.
    Hoyer D; Karpf A
    Eur J Pharmacol; 1988 May; 150(1-2):181-4. PubMed ID: 3402537
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Chronic dexamethasone administration decreases noradrenaline-stimulated, but not serotonin-stimulated, phosphoinositide metabolism in the rat brain.
    Takahashi M; Morinobu S; Totsuka S; Endoh M
    Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):616-20. PubMed ID: 8738294
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. In vitro and ex vivo selectivity profile.
    Malgouris C; Flamand F; Doble A
    Eur J Pharmacol; 1993 Mar; 233(1):29-35. PubMed ID: 8386088
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Apparent antinociceptive properties of piperazine-type serotonin agonists: trifluoromethylphenylpiperazine, chlorophenylpiperazine, and MK-212.
    McKearney JW
    Pharmacol Biochem Behav; 1989 Mar; 32(3):657-60. PubMed ID: 2740421
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Serotonin (5-HT2) receptor mediated enhancement of cortical unit activity.
    Neuman RS; Zebrowska G
    Can J Physiol Pharmacol; 1992 Dec; 70(12):1604-9. PubMed ID: 1301238
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.
    Kennett GA; Whitton P; Shah K; Curzon G
    Eur J Pharmacol; 1989 May; 164(3):445-54. PubMed ID: 2767117
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Regional central serotonin-2 receptor binding and phosphoinositide turnover in rats with 5,7-dihydroxytryptamine lesions.
    Butler PD; Pranzatelli MR; Barkai AI
    Brain Res Bull; 1990 Jan; 24(1):125-9. PubMed ID: 2155684
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Activation of 5-HT1C-receptors suppresses excessive wheel running induced by semi-starvation in the rat.
    Wilckens T; Schweiger U; Pirke KM
    Psychopharmacology (Berl); 1992; 109(1-2):77-84. PubMed ID: 1365675
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Interactions of beta-adrenoceptor agonists and antagonists with the 5-hydroxytryptamine2 (5-HT2) receptor.
    Green AR; Johnson P; Nimgaonkar VL
    Neuropharmacology; 1983 May; 22(5):657-60. PubMed ID: 6136009
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Receptor-mediated stimulation of aortic prostacyclin release by 5-hydroxytryptamine.
    Hirafuji M; Akiyama Y; Ogura Y
    Eur J Pharmacol; 1987 Nov; 143(2):259-65. PubMed ID: 3121367
    [TBL] [Abstract][Full Text] [Related]  

  • 97. 5-Hydroxytryptamine stimulates the formation of inositol phosphate in astrocytes from different regions of the brain.
    Hansson E; Simonsson P; Alling C
    Neuropharmacology; 1987 Sep; 26(9):1377-82. PubMed ID: 2823165
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evidence that blockade of post-synaptic 5-HT1 receptors elicits feeding in satiated rats.
    Dourish CT; Clark ML; Fletcher A; Iversen SD
    Psychopharmacology (Berl); 1989; 97(1):54-8. PubMed ID: 2496427
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cyclic GMP inhibits phosphoinositide turnover in choroid plexus: evidence for interactions between second messengers concurrently triggered by 5-HT2C receptors.
    Kaufman MJ; Hirata F
    Neurosci Lett; 1996 Mar; 206(2-3):153-6. PubMed ID: 8710174
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of prenatal exposure to antidepressants on 5-HT-stimulated phosphoinositide hydrolysis and 5-HT2 receptors in rat brain.
    Romero G; Toscano E; Del Río J
    Gen Pharmacol; 1994 Sep; 25(5):851-6. PubMed ID: 7835628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.